BioSpace News Archive

RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today announced the appointment of Stuart F. Simpson as an independent member of its board of directors.

Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), announced today that on May 6, 2020 it provided a $20 million venture loan facility to Magnolia Medical Technologies, Inc.

Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced its participation in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, at 10:00 a.m. ET.

Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2020 Jefferies Virtual Healthcare Conference as follows

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:30 p.m. ET.

the National Institute for Innovation in Biopharmaceutical Manufacturing announces that they have received $8.9 million from the U.S. Department of Commerce’s National Institute of Standards and Technology.

Jim Green, Chairman, President & Chief Executive Officer of Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today issued a letter to shareholders updating them on the Company’s execution against the key strategic actions committed to in September 2019 to position Harvard Bioscience for long-term profitable growth.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

The U.S. Food and Drug Administration today granted approval to VESIcare LS (solifenacin succinate) oral suspension, a liquid taken by mouth, for the treatment of neurogenic detrusor overactivity (NDO), a form of bladder dysfunction related to neurological impairment, in children ages two years and older.